Serum Level of Antibodies Against Novel Acinetobacter Baumannii OmpA-selected Peptides in ICU Staff: Promise for the Future of Vaccine Development.

IF 1.2 4区 医学 Q4 ALLERGY
Shadi Paydarfar, Mohammad Amin Abbasi, Ali Hashemi, Sodabe Taheri, Mojgan Bandehpour, Nariman Mosaffa
{"title":"Serum Level of Antibodies Against Novel Acinetobacter Baumannii OmpA-selected Peptides in ICU Staff: Promise for the Future of Vaccine Development.","authors":"Shadi Paydarfar,&nbsp;Mohammad Amin Abbasi,&nbsp;Ali Hashemi,&nbsp;Sodabe Taheri,&nbsp;Mojgan Bandehpour,&nbsp;Nariman Mosaffa","doi":"10.18502/ijaai.v22i2.12676","DOIUrl":null,"url":null,"abstract":"<p><p>Extensively drug-resistant Acinetobacter baumannii is considered one of the most dangerous threats to global health, requiring novel therapeutic interventions. The outer membrane protein A (OmpA) is an immunogenic agent that triggers immune responses. The current study evaluated serum antibody levels against previously determined immunogenic OmpA peptides from A baumannii in ICU staff. Serum samples were collected from 62 ICU staff members (representing the exposed group), healthy controls (representing the nonexposed group), and patients with systemic lupus erythematosus (SLE) (as controls for nonspecific antibody reactions). After excluding the cross-reactive antibodies via Escherichia coli lysate pretreatment, all the samples were assessed in the vicinity of A baumannii lysate by enzyme-linked immunosorbent assay (ELISA). All the positive samples were assessed for interaction with previously designed and selected peptides using ELISA. The protective potential of positive serum antibodies was surveyed in vitro using an opsonophagocytic study. The most antibody positive samples against one of the dominant peptides were determined in the ICU personnel (75%).  SLE serum samples did not react with candidate peptides. The strongest positive reaction was observed in serum treatment with one of the OmpA peptides (No. 5) with significant differences compared to other designed peptides. Our findings showed that ICU samples have substantially higher antibody levels than the nonexposed group; Positive samples show strong results in the opsonophagocytosiis assay. This study demonstrates A baumannii colonization at human mucosal surfaces, especially in exposed healthy workers. Novel OmpA-derived peptides could be used to identify immunogenic vaccine candidates. Therefore, more studies are needed  before this peptide and antibody levels are used in diagnosis, prevention, or treatment.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of allergy, asthma, and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18502/ijaai.v22i2.12676","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1

Abstract

Extensively drug-resistant Acinetobacter baumannii is considered one of the most dangerous threats to global health, requiring novel therapeutic interventions. The outer membrane protein A (OmpA) is an immunogenic agent that triggers immune responses. The current study evaluated serum antibody levels against previously determined immunogenic OmpA peptides from A baumannii in ICU staff. Serum samples were collected from 62 ICU staff members (representing the exposed group), healthy controls (representing the nonexposed group), and patients with systemic lupus erythematosus (SLE) (as controls for nonspecific antibody reactions). After excluding the cross-reactive antibodies via Escherichia coli lysate pretreatment, all the samples were assessed in the vicinity of A baumannii lysate by enzyme-linked immunosorbent assay (ELISA). All the positive samples were assessed for interaction with previously designed and selected peptides using ELISA. The protective potential of positive serum antibodies was surveyed in vitro using an opsonophagocytic study. The most antibody positive samples against one of the dominant peptides were determined in the ICU personnel (75%).  SLE serum samples did not react with candidate peptides. The strongest positive reaction was observed in serum treatment with one of the OmpA peptides (No. 5) with significant differences compared to other designed peptides. Our findings showed that ICU samples have substantially higher antibody levels than the nonexposed group; Positive samples show strong results in the opsonophagocytosiis assay. This study demonstrates A baumannii colonization at human mucosal surfaces, especially in exposed healthy workers. Novel OmpA-derived peptides could be used to identify immunogenic vaccine candidates. Therefore, more studies are needed  before this peptide and antibody levels are used in diagnosis, prevention, or treatment.

ICU工作人员抗新型鲍曼不动杆菌ompa选择肽的血清抗体水平:疫苗开发的未来前景
广泛耐药鲍曼不动杆菌被认为是对全球健康最危险的威胁之一,需要新的治疗干预措施。外膜蛋白A (OmpA)是一种触发免疫反应的免疫原性因子。目前的研究评估了ICU工作人员针对先前确定的鲍曼杆菌免疫原性OmpA肽的血清抗体水平。从62名ICU工作人员(代表暴露组)、健康对照(代表未暴露组)和系统性红斑狼疮(SLE)患者(作为非特异性抗体反应的对照)中收集血清样本。经大肠杆菌裂解液预处理排除交叉反应性抗体后,采用酶联免疫吸附试验(ELISA)在鲍曼原虫裂解液附近进行评估。所有阳性样品均使用ELISA评估其与先前设计和选择的肽的相互作用。在体外用调理噬细胞法研究了阳性血清抗体的保护潜能。针对其中一种优势肽的抗体阳性样本最多的是ICU人员(75%)。SLE血清样本与候选肽没有反应。其中一种OmpA肽(No. 5)在血清处理中观察到最强的阳性反应,与其他设计的肽相比有显著差异。我们的研究结果显示,ICU样本的抗体水平明显高于未暴露组;阳性样品在调理噬噬试验中显示出很强的结果。本研究证实了鲍曼原虫在人体粘膜表面的定植,特别是在暴露的健康工人中。新的ompa衍生肽可用于鉴定免疫原性候选疫苗。因此,在将这种多肽和抗体水平用于诊断、预防或治疗之前,还需要进行更多的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
6.70%
发文量
64
审稿时长
>12 weeks
期刊介绍: The Iranian Journal of Allergy, Asthma and Immunology (IJAAI), an international peer-reviewed scientific and research journal, seeks to publish original papers, selected review articles, case-based reviews, and other articles of special interest related to the fields of asthma, allergy and immunology. The journal is an official publication of the Iranian Society of Asthma and Allergy (ISAA), which is supported by the Immunology, Asthma and Allergy Research Institute (IAARI) and published by Tehran University of Medical Sciences (TUMS). The journal seeks to provide its readers with the highest quality materials published through a process of careful peer reviews and editorial comments. All papers are published in English.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信